The study, published in Signal Transduction and Targeted Therapy, tracked 60 patients treated with either 200 mg or 400 mg doses of the drug. At the 400 mg level, the best overall response rate reached 86.2% at 24 weeks, while failure-free survival hit 89.4%. These results provide a potential new avenue for patients facing the immune dysregulation and fibrosis characteristic of cGvHD, a life-threatening complication where donor stem cells attack the recipient's healthy tissues.
Graviton’s GV101 Outperforms Existing Therapies for Chronic GvHD
A Phase Ib/II trial of the ROCK2 inhibitor GV101 has demonstrated an 86.2% response rate in patients with chronic Graft versus Host Disease who had previously failed at least two lines of therapy, significantly outpacing the efficacy benchmarks set by current FDA-approved treatments for the condition.
Clinical data suggest the treatment offers a favorable safety profile compared to standard therapies. Notably, researchers reported no evidence of hematopoietic toxicity or increased infection rates. The most common adverse event, transient bilirubin elevation, was linked to reversible enzymatic inhibition rather than liver damage. Graviton BioScience Corporation, led by founder Dr. Samuel Waksal, is now moving toward Phase III randomized controlled trial planning, intending to prioritize the 400 mg dosage for future development.
Comments (0)
No comments yet. Be the first!